Digestive Tract Reconstruction After Gastrectomy of Gastric Cancer With Type 2 Diabetes
The Effect of Blood Glucose to Different Digestive Tract Reconstruction After Gastrectomy of Gastric Cancer With Type 2 Diabetes
1 other identifier
observational
60
1 country
1
Brief Summary
Different digestive tract reconstruction will affect the blood glucose level of gastric cancer with type 2 diabetes. Subtotal gastrectomy with Billroth II reconstruction and total gastrectomy with Roux-en-Y reconstruction may help to improve glycaemic control which includes fasting blood glucose, postprandial blood glucose, glycosylated hemoglobin, C -peptide and body weight of gastric cancer patients with type 2 diabetes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Aug 2012
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 6, 2012
CompletedFirst Posted
Study publicly available on registry
July 11, 2012
CompletedStudy Start
First participant enrolled
August 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2016
CompletedFebruary 17, 2016
August 1, 2012
4.2 years
July 6, 2012
February 14, 2016
Conditions
Study Arms (4)
Subtotal gastrectomy , BillrothⅠ
Subtotal gastrectomy , BillrothⅡ
total gastrectomy, jejunal interposition
total gastrectomy , Roux-en-Y
Interventions
Subtotal gastrectomy with BillrothⅠ or BillrothⅡ, total gastrectomy with jejunal interposition or Roux-en-Y reconstruction
Eligibility Criteria
gastric cancer with type 2 diabetes,18\~75 years old,without serious underlying diseases
You may qualify if:
- years old,gastric cancer ,can be performed operation
- with type 2 diabetes,fasting blood glucose \> 6.1mmol/L
- without serious underlying diseases which may affect the metabolism and nutrient uptake
- without serious underlying diseases which may affect anesthesia and operation
- can be performed subtotal or total gastrectomy, predicted survival period \> 6months
- no other abdominal operation
- preoperation consultation
- informed consent
You may not qualify if:
- recurrent,metastasis or die
- patient requests for quit
- pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Zhao Yan, Doctor
Tianjin Medical University Cancer Institute and Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 6, 2012
First Posted
July 11, 2012
Study Start
August 1, 2012
Primary Completion
October 1, 2016
Study Completion
December 1, 2016
Last Updated
February 17, 2016
Record last verified: 2012-08